## Hannah Rosenblum

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3024687/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	TTR (Transthyretin) Stabilizers Are Associated With Improved Survival in Patients With TTR Cardiac Amyloidosis. Circulation: Heart Failure, 2018, 11, e004769.	3.9	78
2	Indications for and Findings on Transthoracic Echocardiography in COVID-19. Journal of the American Society of Echocardiography, 2020, 33, 1278-1284.	2.8	74
3	Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis. European Journal of Heart Failure, 2021, 23, 250-258.	7.1	71
4	Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis. Circulation Research, 2021, 128, 1554-1575.	4.5	52
5	The Prognostic Value of Electrocardiogram at Presentation to Emergency Department in Patients With COVID-19. Mayo Clinic Proceedings, 2020, 95, 2099-2109.	3.0	43
6	Peak Cardiac Power Measured Noninvasively With a Bioreactance Technique Is a Predictor of Adverse Outcomes in Patients With Advanced Heart Failure. Congestive Heart Failure, 2010, 16, 254-258.	2.0	22
7	Remote Cardiac Monitoring in Patients With Heart Failure. JAMA Cardiology, 2022, 7, 556.	6.1	22
8	Sex Differences in the Phenotype of Transthyretin Cardiac Amyloidosis Due to Val122Ile Mutation: Insights from Noninvasive Pressure–Volume Analysis. Journal of Cardiac Failure, 2021, 27, 67-74.	1.7	20
9	Comparing outcomes for infiltrative and restrictive cardiomyopathies under the new heart transplant allocation system. Clinical Transplantation, 2020, 34, e14109.	1.6	14
10	Untangling the physiology of transthyretin cardiac amyloidosis by leveraging echocardiographically derived pressure–volume indices. European Heart Journal, 2020, 41, 1448-1450.	2.2	9
11	Surveillance for disease progression of transthyretin amyloidosis after heart transplantation in the era of novel disease modifying therapies. Journal of Heart and Lung Transplantation, 2022, 41, 199-207.	0.6	9
12	Racial Differences in Val122Ile-Associated Transthyretin Cardiac Amyloidosis. Journal of Cardiac Failure, 2022, 28, 950-959.	1.7	8
13	Bionic women and men ―Part 3: Right ventricular dysfunction in patients implanted with left ventricular assist devices. Experimental Physiology, 2020, 105, 759-762.	2.0	6
14	Increased Aortic Stiffness Is Associated With Higher Rates of Stroke, Gastrointestinal Bleeding and Pump Thrombosis in Patients With a Continuous Flow Left Ventricular Assist Device. Journal of Cardiac Failure, 2021, 27, 696-699.	1.7	5
15	Bionic women and men ―Part 2: Arterial stiffness in heart failure patients implanted with left ventricular assist devices. Experimental Physiology, 2020, 105, 755-758.	2.0	3
16	Impact of socioeconomic deprivation on evaluation for heart transplantation at an urban academic medical center. Clinical Transplantation, 2022, 36, e14652.	1.6	3
17	Beyond the Valve and into the Muscle: A Review of Coexisting Aortic Stenosis and Transthyretin Cardiac Amyloidosis. Structural Heart, 2019, 3, 462-468.	0.6	2
18	Theoretical considerations for a left atrial pump in heart failure with preserved ejection fraction. Heart Failure Reviews, 2021, , 1.	3.9	2

#	Article	IF	CITATIONS
19	158 Racial differences in val122lle associated transthyretin cardiac amyloidosis. European Heart Journal Supplements, 2021, 23, .	0.1	0